Adoption and Implementation of Framework Contracting for Essential Medicines in Ghana: Qualitative Insights from Stakeholders

Imagine a country where the government promises free or affordable medicine to its people, yet the shelves in local clinics often sit empty. This is not a failure of will, but a failure of the complex machinery that moves medicine from a factory to a patient's hand. In Ghana, this machinery involves dozens of different groups: the central government that sets the rules, regional offices that manage warehouses, hospitals that dispense the drugs, insurance agencies that pay the bills, and the private companies that actually sell the medicines. When these groups do not move in sync, the system stalls. For years, Ghana struggled with a patchwork of purchasing methods where every hospital or region bought medicines on its own, leading to inconsistent prices, long delays, and frequent shortages. To fix this, the government tried a new approach called framework contracting. Think of it as a master agreement: instead of every hospital running its own race to buy medicine every time it runs low, the government negotiates a single, long-term deal with a few trusted suppliers. This deal sets the price and the terms for a year or more, allowing hospitals to simply "call off" what they need when they need it, without starting the whole bidding process over again. The hope was that this would lower costs, speed up delivery, and ensure that essential medicines were always available.

A team of researchers set out to see if this new system was working as intended. They did not just look at the numbers on a spreadsheet; they went to the source. They interviewed ten senior people who hold the keys to the system: officials from the Ministry of Health, representatives from the National Health Insurance Authority, leaders of the regional medical stores, the public procurement authority, and even the pharmaceutical suppliers themselves. They also pored over eleven official documents, including the laws that created the system, reports on how the system was designed, and evaluations of how well the system was performing. Their goal was to understand not just what the plan was on paper, but how it felt and functioned in the real world for the people who had to make it work.

The researchers found that the new system did succeed in some very specific ways. By centralizing the buying power, the government managed to negotiate significantly lower prices for the medicines. The time it took for suppliers to deliver the goods also dropped dramatically, falling from nearly 188 days in the first round of the program to about 80 days later on. In the language of the contract, the deal was a success: the government got better prices and faster delivery times. However, the story took a sharp turn when the researchers looked at whether the medicines actually arrived at the clinics. Despite the lower prices and faster delivery times, the shelves in the hospitals were still often empty. The study revealed a troubling disconnect: the system was buying the medicine efficiently, but the medicine was not reaching the patients.

The reason for this gap lies in how the contract was designed and how the money flows through the system. Under the new arrangement, the central Ministry of Health negotiates the price with the suppliers, but it does not pay the bill. Instead, the payment responsibility falls on regional health offices and individual hospitals. These local units must pay using funds that come from the national health insurance scheme. The problem is that the insurance scheme often pays these local units very slowly, leaving them with no money to settle their bills with the suppliers. When a supplier delivers medicine to a hospital that already owes them money, and the insurance company has not yet paid the hospital, the supplier faces a choice. The researchers found that suppliers, acting rationally to protect their own businesses, began to withhold supplies from these indebted facilities. They would deliver to those who could pay immediately but stop sending goods to those who were stuck in a cycle of unpaid debts.

The study also highlighted that the contract itself created a trap for the suppliers. The prices were fixed in the local currency, the Ghanaian cedi, for the entire year, with no automatic way to adjust if the value of the currency dropped or if inflation rose. At the same time, the amount of medicine the government promised to buy was only a suggestion, not a guaranteed order. This meant suppliers faced a double risk: they could lose money if the currency changed, and they had no guarantee they would sell the full amount they were asked to supply. Faced with these risks and the reality of slow payments, suppliers adjusted their behavior. They started charging higher prices in their initial bids to cover the risk, or they simply stopped supplying to the most indebted areas. The researchers noted that this was not because the suppliers were failing to do their jobs, but because the rules of the game encouraged them to protect themselves from financial loss.

The interviews painted a picture of a system where everyone was trying to do their part, but the pieces did not fit together. The central government felt they had done their job by securing a good price. The local hospitals felt they were doing their job by ordering what they needed. The insurance agency was processing payments as fast as their system allowed. But because the timing of the payments did not match the timing of the deliveries, the chain broke. The suppliers, caught in the middle, became the bottleneck. They were not refusing to sell; they were reacting to a system where the risk of non-payment was too high to ignore. The researchers concluded that the problem was not that the new contract was a bad idea, but that it was treated as a simple purchasing tool when it was actually a complex health system intervention. You cannot fix the availability of medicine just by changing how you buy it; you must also fix how you pay for it and how the different parts of the system talk to each other.

The study suggests that for this system to truly work, the design needs to change. The government needs to create a way to adjust prices automatically if the currency value shifts, so suppliers do not have to guess the risk. They need to ensure that the local units have the money to pay the suppliers on time, perhaps by guaranteeing payment or changing how the insurance funds are released. The researchers argue that simply telling suppliers to "do better" or telling hospitals to "order better" will not solve the problem. The solution lies in aligning the incentives so that when a supplier delivers medicine, they are confident they will get paid. Until the financial risks are managed and the payment chain is reliable, the lower prices and faster delivery times will remain a victory on paper, but the clinics will continue to face shortages. The lesson here is clear: in a complex system, a smart contract is not enough; the entire ecosystem of money, trust, and coordination must be strong enough to support it.